John Milligan Acquires 75,000 Shares of 4D Molecular Therapeutics

John Milligan made a notable move by purchasing 75,000 shares of 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT) on June 17, 2026. This insider transaction did not specify a purchase price or total value.

Other Institutional Activity in 4D Molecular Therapeutics

Janus Henderson Group PLC increased its holdings in 4D Molecular Therapeutics by 611,276 shares, bringing its total to 5,247,151 shares valued at about $48.9 million. Meanwhile, RA Capital Management, L.P. reduced its position by 603,432 shares, leaving it with 5,049,779 shares worth approximately $47 million. Goldman Sachs Group Inc. also trimmed its stake by 97,467 shares, ending with 4,205,438 shares valued at around $39.2 million. BlackRock, Inc. added 80,427 shares, reaching a total of 4,145,303 shares, valued at roughly $38.6 million. Novo Holdings A/S maintained its position with 3,650,737 shares valued at $33.9 million.

4D Molecular Therapeutics Stock Snapshot

Shares of 4D Molecular Therapeutics are trading near $9.66. The company has a market cap of $504.99 million and a beta of 2.756, which indicates higher volatility compared to the market. The stock has seen a 52-week low of $3.68 and a high of $12.34. The 50-day moving average is $9.43, while the 200-day moving average stands at $9.24. The company has a strong current ratio of 9.34 and a quick ratio of 9.01, reflecting solid liquidity. However, it faces a high debt-to-equity ratio of 4.545.

Recent Earnings

4D Molecular Therapeutics reported revenue of $88.24 million, growing by 216.64% from the previous period. Despite this growth, the company remains unprofitable, with a net margin of -182.34% and a return on equity of -34.92%. The next earnings announcement is scheduled for August 10, 2026.

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

Alongside John Milligan, several other insiders also purchased shares on June 17, 2026. Charles Theuer, Glenn Sblendorio, Susannah Gray, Jacob Chacko, and Nancy Miller-Rich each bought 50,000 shares. None of these transactions were reported as planned under Rule 10b5-1.

Analysts Set New Price Targets

On March 30, 2026, Jefferies assumed coverage with a 'buy' rating and a $21 price target. HC Wainwright & Co. reiterated their 'buy' rating with a $36 target on March 20, 2026. RBC Capital maintained its 'buy' rating, setting a $35 target on March 19, 2026. The consensus among nine analysts is a 'buy' rating, with a target mean price of $28.22.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a biotechnology firm based in Emeryville, California. It focuses on developing adeno-associated virus vectors through its proprietary platform, Therapeutic Vector Evolution. The company’s lead product candidate, 4D-150, targets retinal vascular diseases. Other pipeline projects include 4D-710 for cystic fibrosis and preclinical candidates like 4D-175 for geographic atrophy and 4D-725 for alpha-1 anti-trypsin deficiency lung disease. Founded in 2013, the firm employs 196 people and collaborates with Otsuka Pharmaceutical Co., Ltd.

Bottom Line

John Milligan's acquisition of 75,000 shares in 4D Molecular Therapeutics reflects continued interest in the company's potential within the biotechnology sector. Investors should note that insider transactions are disclosed after they occur and may not indicate current positions. With strong institutional interest and positive analyst ratings, 4D Molecular Therapeutics remains a company to watch in the evolving biotech landscape.